# A new hope for pulmonary hypoplasia: amniotic fluid stem cell extracellular vesicles?

## TL;DR

This study explores using amniotic fluid stem cell extracellular vesicles to treat underdeveloped lungs in a rat model of congenital diaphragmatic hernia.

## Contribution

The study demonstrates that AFSC-EVs can reduce inflammation and improve fetal lung development in a CDH rat model.

## Key findings

- Fetal hypoplastic lungs in CDH rat models show a pronounced inflammatory signature with increased macrophage density.
- Intra-amniotic AFSC-EV administration reduced inflammation and enhanced lung development through branching morphogenesis and epithelial maturation.

## Abstract

In a recent study, Antounians and colleagues (2024) investigated the potential of amniotic fluid stem cell-derived extracellular vesicles (AFSC-EVs) as a therapeutic intervention for pulmonary hypoplasia resulting from congenital diaphragmatic hernia (CDH). They demonstrated the pronounced inflammatory signature of the fetal hypoplastic lungs, marked by heightened macrophage density in a CDH rat model. Intra-amniotic AFSC-EV administration mitigated the inflammatory process and enhanced fetal lung development by promoting branching morphogenesis and epithelial maturation. These findings add to a growing body of preclinical and clinical evidence supporting the therapeutic potential of AFSC-EVs for inflammation-driven pathologies.